Aldeyra Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Aldeyra Therapeutics Inc Unternehmen

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Aldeyra Therapeutics Inc Informationen



BörsenkürzelALDX

Name des UnternehmensAldeyra Therapeutics Inc

IPO-datumMay 02, 2014

CEODr. Todd C. Brady, M.D., Ph.D.

Anzahl der mitarbeiter9

WertpapierartOrdinary Share

GeschäftsjahresendeMay 02

Addresse131 Hartwell Avenue

StadtLEXINGTON

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl02421

Telefon17817614904

Websitehttps://www.aldeyra.com/

BörsenkürzelALDX

IPO-datumMay 02, 2014

CEODr. Todd C. Brady, M.D., Ph.D.

Führungskräfte von Aldeyra Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

Dr. Ben R. Bronstein, M.D.

Independent Director

--

Ms. Nancy B. Miller-Rich

Independent Director

--

Mr. William (Chip) Clark

Independent Director

--

Mr. Michael (Mike) Alfieri

Principal Financial Officer and Principal Accounting Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Todd C. Brady, M.D., Ph.D.

President, Chief Executive Officer, Director

1.42M

+23.16%

Dr. Richard H. Douglas, Ph.D.

Independent Chairman of the Board

125.00K

--

Mr. Martin J. Joyce

Independent Director

23.97K

--

Dr. Gary M. Phillips, M.D.

Independent Director

14.81K

--

Dr. Neal S. Walker

Independent Director

--

Dr. Stephen G. Machatha, Ph.D.

Chief Development Officer

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Wed, Oct 1

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Knoll Capital Management, LLC

9.10%

Perceptive Advisors LLC

6.73%

The Vanguard Group, Inc.

5.97%

BlackRock Institutional Trust Company, N.A.

5.88%

Ardsley Advisory Partners LP

3.41%

Andere

68.91%

Aktionäre

Anteil

Knoll Capital Management, LLC

9.10%

Perceptive Advisors LLC

6.73%

The Vanguard Group, Inc.

5.97%

BlackRock Institutional Trust Company, N.A.

5.88%

Ardsley Advisory Partners LP

3.41%

Andere

68.91%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

19.07%

Investment Advisor

18.01%

Investment Advisor/Hedge Fund

11.66%

Private Equity

6.76%

Individual Investor

3.10%

Research Firm

2.16%

Family Office

0.25%

Pension Fund

0.18%

Bank and Trust

0.09%

Andere

38.72%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

279

34.71M

57.96%

-3.49M

2025Q2

295

35.94M

60.00%

-7.70M

2025Q1

315

40.31M

67.37%

-4.94M

2024Q4

306

39.84M

66.72%

-5.42M

2024Q3

295

38.52M

64.82%

-5.60M

2024Q2

290

37.23M

62.65%

-8.21M

2024Q1

294

37.04M

62.88%

-7.70M

2023Q4

296

36.84M

62.63%

-6.52M

2023Q3

298

39.89M

68.07%

-12.41M

2023Q2

305

41.03M

70.05%

-8.66M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Knoll Capital Management, LLC

5.48M

9.14%

--

Jun 30, 2025

Perceptive Advisors LLC

4.05M

6.76%

-824.22K

-16.90%

Jun 30, 2025

The Vanguard Group, Inc.

3.50M

5.85%

-216.43K

-5.82%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.54M

5.91%

+127.13K

+3.73%

Jun 30, 2025

Ardsley Advisory Partners LP

2.05M

3.42%

+300.00K

+17.14%

Jun 30, 2025

AQR Capital Management, LLC

1.47M

2.46%

+1.08M

+275.44%

Jun 30, 2025

Brady (Todd C)

1.42M

2.38%

+267.69K

+23.16%

Apr 14, 2025

Kingdon Capital Management, L.L.C.

1.33M

2.22%

+552.79K

+70.96%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.15M

1.91%

+8.77K

+0.77%

Jun 30, 2025

683 Capital Management LLC

1.08M

1.8%

+604.00K

+126.89%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Invesco NASDAQ Future Gen 200 ETF

0.43%

Vanguard US Momentum Factor ETF

0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.05%

iShares Micro-Cap ETF

0.05%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

Global X Russell 2000 ETF

0.01%

Avantis US Small Cap Equity ETF

0.01%

Proshares Ultra Russell 2000

0.01%

iShares Russell 2000 ETF

0.01%

ProShares Hedge Replication ETF

0.01%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.43%

Vanguard US Momentum Factor ETF

Anteil0.06%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Anteil0.05%

iShares Micro-Cap ETF

Anteil0.05%

Invesco RAFI US 1500 Small-Mid ETF

Anteil0.02%

Global X Russell 2000 ETF

Anteil0.01%

Avantis US Small Cap Equity ETF

Anteil0.01%

Proshares Ultra Russell 2000

Anteil0.01%

iShares Russell 2000 ETF

Anteil0.01%

ProShares Hedge Replication ETF

Anteil0.01%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten